Fig. 4: Targeting SGLT1 reduced the development of acquired resistance to EGFR TKI in vivo.
From: PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs
a The growth rate of xenograft tumors of H292 cells in response to treatments with erlotinib, phlorizin, or the combination was determined by measuring tumor size. b The representative IHC staining of tumor sections from (a) were shown (left) and the results from five independent sections for all groups were quantitated with H-score (Right). Scale bar, 50 μm. c–e SCID mice injected with A549-Luc cells were treated with erlotinib, phlorizin, or the combination. The tumor volumes were measured by detecting luminescent signals in the lumina LT in vivo imaging system (upper in panel (c)) and the luciferase activity was quantitated (lower in panel (c)). After treatment for 3 weeks, the lungs of A549 cell-xenograft SCID mice were harvested and the numbers of lung tumor nodules were quantitated. e The representative IHC staining of tumor sections from (d) was shown (left) and the results from five independent sections for all groups were quantitated with H-score (Right). Scale bar, 50 μm. Data represent mean ± sd *p < 0.05 and **p < 0.01 vs. control, Student’s t-test.
